Somatropin - Norditropin (Novo Nordisk) - Complete Research Paper

1. Summary

Norditropin is a recombinant human growth hormone (rhGH, somatropin) manufactured by Novo Nordisk for the treatment of growth disorders in children and growth hormone deficiency in adults. It is distinguished by its FlexPro prefilled pen delivery system and unique room-temperature stability—features that significantly enhance patient convenience compared to other somatropin products.

FDA Approval: Initial U.S. approval 1987; FlexPro device approved 2007 Manufacturer: Novo Nordisk

Historical Milestones:

• 1988: Norditropin introduced
• 1999: First liquid GH formulation (Norditropin SimpleXx)
• 2004: First prefilled GH pen (NordiFlex)
• 2007: FlexPro pen system approved
• 2015: FlexPro 30 mg/3.0 mL approved

Norditropin is produced using recombinant DNA technology and contains 191-amino acid somatropin identical to natural human pituitary growth hormone.

Key Clinical Features:

• Drug class: Recombinant human growth hormone (somatropin)
• Molecular weight: ~22,125 daltons (191 amino acids)
• Administration: Subcutaneous injection via prefilled FlexPro pen
• Half-life: 7-10 hours (SC); 21 minutes (IV)
• Dosing: Daily (typically evening)
• Generic: Not available (brand only)

Distinguishing Features: | Feature | Norditropin Advantage | |------

Goal Relevance:

• Help my child grow taller if they have growth hormone deficiency.
• Support my child's growth and development if they have Noonan syndrome.
• Improve my child's height if they have Turner syndrome.
• Assist my child in gaining height if they were born small for their gestational age.
• Enhance my child's growth and body composition if they have Prader-Willi syndrome.
• Boost my muscle growth and strength as an adult with growth hormone deficiency.
• Aid in my recovery and overall health if I have multiple hormone deficiencies.

---|----------------------| | Ready-to-use | No reconstitution required | | Room temperature stability | Up to 3 weeks after first use at ≤77°F | | Prefilled pen | FlexPro—simple, convenient device | | Noonan syndrome | Unique FDA-approved indication | | Dosing precision | Multiple pen strengths with fine increments |

2. Mechanism of Action

Norditropin functions identically to natural pituitary-derived human growth hormone, binding to GH receptors on target cells throughout the body.

Primary Mechanism:

1. GH Receptor Binding: Somatropin binds to GHR on target cell membranes
2. Receptor Dimerization: Triggers receptor activation
3. Signal Transduction: Activates JAK2-STAT5, MAPK, and PI3K pathways
4. Gene Transcription: Promotes growth-related gene expression
5. IGF-I Production: Stimulates hepatic IGF-I synthesis

Direct Effects:

• Skeletal growth: Stimulates chondrocyte proliferation at epiphyses
• Muscle growth: Promotes protein synthesis, increases lean mass
• Bone metabolism: Enhances bone formation and turnover
• Organ growth: Stimulates visceral organ development

Metabolic Effects:

IGF-I Mediation: Most growth-promoting effects are mediated through IGF-I:

• Linear bone growth
• Cartilage formation
• Cell proliferation and differentiation
• Muscle development

Condition-Specific Effects:

Noonan Syndrome (Unique Indication):

• Promotes linear growth in children with Noonan syndrome
• Addresses short stature component of this genetic disorder
• Effects similar to Turner syndrome growth promotion

Prader-Willi Syndrome:

• Improves linear growth
• Favorable changes in body composition
• Requires careful monitoring for respiratory issues

3. FDA-Approved Indications

Pediatric Indications:

Unique Indication - Noonan Syndrome: Norditropin is one of the few somatropin products with FDA approval for short stature associated with Noonan syndrome. This genetic disorder affects development in various body parts and is characterized by short stature, heart defects, and distinctive facial features.

Adult Indication:

Adult GHD Etiologies Include:

• Pituitary disease
• Hypothalamic disease
• Surgery
• Radiation therapy
• Trauma
• Multiple hormone deficiencies (hypopituitarism)

Regulatory Status:

4. Dosing and Administration

General Principles:

• Individualize dosage based on patient response
• Divide calculated weekly dose into 6-7 daily doses
• Administer preferably in evening
• Use IGF-I levels and clinical response to guide adjustments

Pediatric Dosing by Indication:

Adult GHD Dosing:

Weight-Based Regimen:

• Starting: 0.004 mg/kg/day
• Maximum: 0.016 mg/kg/day (after ~6 weeks titration)

Non-Weight-Based Regimen (Preferred):

• Starting: 0.2 mg/day (range 0.15-0.30 mg/day)
• Increase by 0.1-0.2 mg/day every 1-2 months
• Adjust based on clinical response, IGF-I, and adverse effects

Special Dosing Considerations:

FlexPro Pen Strengths and Dosing:

FlexPro Advantages:

• No reconstitution required
• Ready-to-use prefilled pen
• Compatible with FlexPro PenMate (hides needle)
• Simple dial-a-dose mechanism

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous injection
• Bioavailability: Approximately 70-80%
• Absorption characteristic: Slow absorption from SC site determines observed half-life

Distribution:

• Distributes to liver, kidney, muscle, bone, and target tissues
• Pharmacokinetics similar in pediatric and adult patients

Metabolism:

• Primary: Liver and kidney (protein catabolism)
• Metabolized to smaller peptides and amino acids
• No significant CYP450 involvement

Elimination:

Clearance:

• IV infusion: 2.3 ± 1.8 mL/min/kg (139 ± 105 mL/min)
• The longer SC half-life reflects slow absorption from the injection site (flip-flop kinetics)

Special Populations:

6. Side Effects and Adverse Reactions

Common Adverse Events:

Adults with GHD:

Pediatric Patients:

• Injection site reactions
• Headache
• Hypothyroidism
• Mild hyperglycemia
• Upper respiratory infections

Serious Adverse Reactions:

Norditropin is contraindicated in critically ill patients.

Pediatric-Specific Serious Events:

• Slipped capital femoral epiphysis (SCFE) - July 2025 labeling update emphasizes monitoring
• Legg-Calvé-Perthes disease
• Progression of scoliosis
• Benign intracranial hypertension (pseudotumor cerebri)
• Pancreatitis (rare)

Prader-Willi Syndrome: Reports of sudden death in PWS patients with:

• Severe obesity
• Upper airway obstruction history
• Sleep apnea
• Respiratory infections

Metabolic Effects:

• New-onset or worsening diabetes
• Glucose intolerance
• May unmask central hypothyroidism
• May unmask central adrenal insufficiency

7. Drug Interactions

Glucocorticoids:

• May attenuate growth-promoting effects
• Monitor growth response in patients on corticosteroids
• Glucocorticoid replacement may need adjustment

Thyroid Hormones:

• Somatropin may unmask central hypothyroidism
• Monitor thyroid function regularly
• Untreated hypothyroidism impairs GH response

Insulin and Oral Antidiabetics:

Sex Steroids:

Oral Estrogen:

• May reduce IGF-I response
• Women on oral estrogen may need higher somatropin doses
• Consider transdermal estrogen as alternative

Androgens:

• May enhance growth response
• Monitor for virilization

CYP450 Substrates:

• Somatropin may affect CYP450 metabolism
• Monitor levels of corticosteroids, sex steroids, anticonvulsants, cyclosporin

8. Contraindications

Absolute Contraindications:

1. Acute critical illness due to:

   • Complications following open heart surgery
   • Abdominal surgery
   • Multiple accidental trauma
   • Acute respiratory failure

2. Active malignancy

   • Discontinue if evidence of tumor activity

3. Pediatric patients with closed epiphyses (for growth indications)

4. Prader-Willi syndrome with:

   • Severe obesity
   • History of upper airway obstruction
   • Sleep apnea
   • Severe respiratory impairment

5. Known hypersensitivity to somatropin or excipients

6. Active proliferative or severe non-proliferative diabetic retinopathy

Precautions:

9. Special Populations

Pediatric Use:

• Safety and efficacy established for approved indications
• Monitor growth response, bone age, IGF-I
• Watch for SCFE (hip/knee pain, limping)
• Monitor scoliosis in at-risk patients

Geriatric Use:

• Limited data in patients ≥65 years
• May be more sensitive to effects
• Start with lower doses
• Monitor more frequently

Pregnancy:

• No adequate human studies
• Use only if clearly needed

Lactation:

• Unknown if excreted in milk
• Use caution

Renal Impairment:

• No formal studies
• Reduced clearance expected; use caution

Hepatic Impairment:

• No formal studies
• Reduced clearance expected; use caution

Obesity:

• Non-weight-based dosing recommended
• Higher adverse effect risk

Noonan Syndrome:

• Specific indication for Norditropin
• Doses up to 0.066 mg/kg/day permitted
• Monitor cardiac function (inherent to condition)

10. Monitoring Parameters

Baseline Assessment:

Ongoing Monitoring:

Growth (Pediatric):

Laboratory:

Clinical:

11. Cost and Availability

Pricing (United States, 2024-2025):

Generic/Biosimilar Status:

• Generic: Not available (brand only)
• Biosimilar: Anticipated competition 2025+

Insurance Coverage:

• Coverage varies by plan and diagnosis
• Prior authorization typically required
• Medicare: Limited coverage

Patient Assistance Programs:

Norditropin Savings Card (Novo Nordisk):

Patient Assistance Program:

• Free medication for eligible uninsured patients
• Income-based eligibility
• Enroll via healthcare provider

NovoCare Support:

• Dedicated Case Manager assistance
• Insurance coverage support
• Reimbursement help
• Contact: 1-888-NOVO-444 (1-888-668-6444)

12. Clinical Evidence Summary

Clinical Development: Norditropin has extensive clinical data since 1987 approval, with continuous innovation in delivery systems.

Pediatric GHD:

• Significant improvement in height velocity
• Normalization of IGF-I levels
• Long-term improved adult height outcomes

Noonan Syndrome (Unique Indication):

• Demonstrated improvement in linear growth
• Height velocity increases comparable to Turner syndrome responses
• Well-tolerated at approved doses

Turner Syndrome:

• Adult height gains of 5-8 cm above predicted
• Optimal response with early initiation

Prader-Willi Syndrome:

• Improved growth and body composition
• Requires careful patient selection and monitoring

Adult GHD:

• Improved body composition
• Enhanced quality of life measures
• Improved exercise capacity

Device Benefits:

• FlexPro convenience improves adherence
• Room temperature stability facilitates travel and daily use
• No reconstitution reduces medication errors

13. Comparison with Alternatives

Comparison of FDA-Approved Somatropin Products:

Norditropin Key Differentiators:

When to Choose Norditropin:

1. Noonan syndrome diagnosis
2. Patient values convenience/travel flexibility
3. Needle anxiety (PenMate option)
4. Preference for no reconstitution
5. Need for room temperature storage
6. Desire for simplest device

14. Storage and Handling

Storage Conditions:

Before First Use:

After First Use:

This room temperature stability is a unique advantage of Norditropin.

Handling:

• No reconstitution required
• Attach new pen needle before each injection
• Prime pen before first use with new cartridge
• Inject subcutaneously (abdomen, thigh, upper arm, buttock)
• Rotate injection sites
• Never share pens between patients

Disposal:

• Dispose of used pens and needles in sharps container
• Follow local regulations

Travel:

• Room temperature storage (up to 3 weeks) facilitates travel
• No ice packs required for short trips
• Protect from freezing and extreme heat

15. References

1. Norditropin Prescribing Information. Novo Nordisk. 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf

2. DailyMed. NORDITROPIN- somatropin injection, solution. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14

3. Novo Nordisk Press Release. FDA Approval for Norditropin FlexPro 30 mg/3.0 mL. January 2015. Available at: https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-for-norditropin-flexpro-30-mg30-ml-for-patients-with-growth-hormone-disorders-300025960.html

4. Norditropin Official Site. Novo Nordisk. Available at: https://www.norditropin.com/

5. Drugs.com. Norditropin: Uses, Dosage, Side Effects, Warnings. Available at: https://www.drugs.com/norditropin.html

6. GoodRx. Norditropin 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/norditropin

7. NovoCare. Norditropin Savings and Support. Available at: https://www.novocare.com/growth-related-disorders/products/norditropin.html

8. NovoMedLink. Norditropin Co-Pay Assistance. Available at: https://www.novomedlink.com/growth-related-disorders/products/treatments/norditropin/cost-coverage/patient-savings.html

9. RxList. Norditropin (Somatropin Injection): Side Effects, Uses, Dosage. Available at: https://www.rxlist.com/norditropin-drug.htm

10. Drugs.com. Norditropin FlexPro Prices, Coupons, Copay Cards & Patient Assistance. Available at: https://www.drugs.com/price-guide/norditropin-flexpro

Document compiled from FDA prescribing information, manufacturer resources, and clinical literature. Last updated: December 2024.

Status: PAPER 70 OF 76 COMPLETE

Next Paper: #71 - Somatropin (Omnitrope)